Acetylsalicylic acid as an adjuvant therapy for schizophrenia

Wijnand Laan; Jean Paul Selten; René S. Kahn; Anne Margriet Huisman; Cobi J. Heijnen; Diederick E. Grobbee; Huibert Burger

doi:10.1186/1745-6215-7-31

Acetylsalicylic acid as an adjuvant therapy for schizophrenia

Wijnand Laan, Jean Paul Selten, René S. Kahn, Anne Margriet Huisman, Cobi J. Heijnen, Diederick E. Grobbee, Huibert Burger

Symptom Research CAO

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Background: Findings from both epidemiological and basic research point to the possibility that NSAIDS impede the deterioration in schizophrenia. Methods: To study the efficacy of acetylsalicylic acid we will perform a randomized placebo controlled double-blind add-on trial of 80 inpatients and outpatients with schizophrenia, schizophreniform or schizoaffective disorder. Patients will be 1:1 randomized to either 3 months 1000 mg acetylsalicylic acid per day or 3 months placebo, in addition to their regular antipsychotic treatment. All patients will receive pantoprazole treatment for gastroprotection. The outcomes of this study are 3-month change in psychotic and negative symptom severity, cognitive function, and several immunological parameters. This trial may (1) yield a new (adjuvant) therapy for schizophrenia and (2) add to the knowledge on the pathogenesis of this major psychiatric disorder.

Original language	English (US)
Article number	31
Journal	Trials
Volume	7
DOIs	https://doi.org/10.1186/1745-6215-7-31
State	Published - Oct 23 2006

ASJC Scopus subject areas

Medicine (miscellaneous)
Pharmacology (medical)

Access to Document

10.1186/1745-6215-7-31

Cite this

@article{6b1aec6719704605bc5177fcd0950d45,

title = "Acetylsalicylic acid as an adjuvant therapy for schizophrenia",

abstract = "Background: Findings from both epidemiological and basic research point to the possibility that NSAIDS impede the deterioration in schizophrenia. Methods: To study the efficacy of acetylsalicylic acid we will perform a randomized placebo controlled double-blind add-on trial of 80 inpatients and outpatients with schizophrenia, schizophreniform or schizoaffective disorder. Patients will be 1:1 randomized to either 3 months 1000 mg acetylsalicylic acid per day or 3 months placebo, in addition to their regular antipsychotic treatment. All patients will receive pantoprazole treatment for gastroprotection. The outcomes of this study are 3-month change in psychotic and negative symptom severity, cognitive function, and several immunological parameters. This trial may (1) yield a new (adjuvant) therapy for schizophrenia and (2) add to the knowledge on the pathogenesis of this major psychiatric disorder.",

author = "Wijnand Laan and Selten, {Jean Paul} and Kahn, {Ren{\'e} S.} and Huisman, {Anne Margriet} and Heijnen, {Cobi J.} and Grobbee, {Diederick E.} and Huibert Burger",

year = "2006",

month = oct,

day = "23",

doi = "10.1186/1745-6215-7-31",

language = "English (US)",

volume = "7",

journal = "Trials",

issn = "1745-6215",

publisher = "BioMed Central",

}

TY - JOUR

T1 - Acetylsalicylic acid as an adjuvant therapy for schizophrenia

AU - Laan, Wijnand

AU - Selten, Jean Paul

AU - Kahn, René S.

AU - Huisman, Anne Margriet

AU - Heijnen, Cobi J.

AU - Grobbee, Diederick E.

AU - Burger, Huibert

PY - 2006/10/23

Y1 - 2006/10/23

N2 - Background: Findings from both epidemiological and basic research point to the possibility that NSAIDS impede the deterioration in schizophrenia. Methods: To study the efficacy of acetylsalicylic acid we will perform a randomized placebo controlled double-blind add-on trial of 80 inpatients and outpatients with schizophrenia, schizophreniform or schizoaffective disorder. Patients will be 1:1 randomized to either 3 months 1000 mg acetylsalicylic acid per day or 3 months placebo, in addition to their regular antipsychotic treatment. All patients will receive pantoprazole treatment for gastroprotection. The outcomes of this study are 3-month change in psychotic and negative symptom severity, cognitive function, and several immunological parameters. This trial may (1) yield a new (adjuvant) therapy for schizophrenia and (2) add to the knowledge on the pathogenesis of this major psychiatric disorder.

AB - Background: Findings from both epidemiological and basic research point to the possibility that NSAIDS impede the deterioration in schizophrenia. Methods: To study the efficacy of acetylsalicylic acid we will perform a randomized placebo controlled double-blind add-on trial of 80 inpatients and outpatients with schizophrenia, schizophreniform or schizoaffective disorder. Patients will be 1:1 randomized to either 3 months 1000 mg acetylsalicylic acid per day or 3 months placebo, in addition to their regular antipsychotic treatment. All patients will receive pantoprazole treatment for gastroprotection. The outcomes of this study are 3-month change in psychotic and negative symptom severity, cognitive function, and several immunological parameters. This trial may (1) yield a new (adjuvant) therapy for schizophrenia and (2) add to the knowledge on the pathogenesis of this major psychiatric disorder.

UR - http://www.scopus.com/inward/record.url?scp=33750480256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750480256&partnerID=8YFLogxK

U2 - 10.1186/1745-6215-7-31

DO - 10.1186/1745-6215-7-31

M3 - Article

C2 - 17059588

AN - SCOPUS:33750480256

SN - 1745-6215

VL - 7

JO - Trials

JF - Trials

M1 - 31

ER -

Acetylsalicylic acid as an adjuvant therapy for schizophrenia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this